



October 19, 2018

✓ **BSE Limited,**  
Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**The National Stock Exchange of India Ltd.,**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI**  
**(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards completion of GMP inspection by the US FDA of the Company's Pithampur Unit-3 (Indore) facility in October, 2018 and also a Pre-Approval Inspection (PAI) for the Company's Tiotropium DPI ANDA. The inspection closed with five observations which are procedural in nature.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully,  
For **LUPIN LIMITED**

*R. V. Satam*

For **R. V. SATAM**  
**COMPANY SECRETARY**



Encl.: a.a.



## Lupin's Pithampur Unit-3 (Indore) Inspected by US FDA

**Mumbai, October 19, 2018:** Pharma major Lupin announced today the completion of a US FDA inspection carried out at its Pithampur Unit-3 (Indore) facility. The inspection was a GMP inspection for the facility and also a Pre-Approval Inspection (PAI) for the company's Tiotropium DPI ANDA. The inspection at the site was conducted between October 8, 2018 and October 18, 2018.

The inspection closed with five observations. These observations are procedural in nature.

### About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8<sup>th</sup> largest generics pharmaceutical company both in terms of market capitalization (30<sup>th</sup> June 2018, Bloomberg) and revenues (31<sup>st</sup> March 2018, Bloomberg LTM) globally. The Company is the 4<sup>th</sup> largest pharmaceutical player in the US by prescriptions (IQVIA MAT June 2018); 3<sup>rd</sup> largest Indian pharmaceutical company by global revenues (31<sup>st</sup> March 2018, Bloomberg LTM); 6<sup>th</sup> largest generic pharmaceutical player in Japan and 5<sup>th</sup> largest company in the Indian Pharmaceutical Market (IQVIA MAT June 2018).

For the financial year ended 31<sup>st</sup> March, 2018, Lupin's Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter – [www.twitter.com/lupinglobal](http://www.twitter.com/lupinglobal)

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3<sup>rd</sup> Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

### For further information or queries please contact –

Pooja Thakran

VP – Corporate Communications

Email: [poojathakran@lupin.com](mailto:poojathakran@lupin.com)

Ph: +91-22-66402531 / 8291013225

Arvind Bothra

Head – Investor Relations

Email: [arvindbothra@lupin.com](mailto:arvindbothra@lupin.com)

Ph: +91-22-66402137

*\*Safe Harbor Statement*